University System of Maryland

The United States Government As Represented by the Department of Veterans Affairs

Biom&eacute;rieux, Inc.

Anthony DeVico

George K Lewis

Alfredo Garzino-Demo

Mohammad Sajadi

Ranajit Pal

Robert C Gallo

Mangalasseril G Sarngadharan

Robert G Tuskan

Phillip D Markham

Timothy R Fouts

Yongjun Guan

Marzena Pazgier

Tongyun Liu

Dongkyoon Kim

Guy Cavet

The present invention provides broadly neutralizing antibodies against HIV, compositions comprising the same and methods of use thereof.

Broadly neutralizing antibodies against HIV

The present invention provides a method of making an antibody by identifying a circulating antibody with activity from a subject comprising i) subjecting biological fluid selected from the group consisting of blood, plasma and serum and combinations thereof from the subject to one or more rounds of affinity chromatography to purify the circulating antibody; ii) optionally further subjecting the circulating antibody to isoelectric focusing to purify the circulating antibody based on charge; iii) testing the purified circulating antibody for activity; iv) digesting the purified circulating antibody from parts i) or ii) to create an antibody fragment; v) subjecting the antibody fragment to mass spectrometry to generate a mass assignment and a deduced amino acid sequence of the antibody fragment; vi) comparing the deduced amino acid sequence with an amino acid sequence of an antibody generated from the subject's B-cells to identify an antibody sequence that matches the deduced amino acid sequence; vii) generating an antibody comprising light chain and heavy chain CDR sequences of the B-cell antibody that matches the deducted amino acid sequence of party vi); and viii) testing the antibody of part vii) for activity.

Methods of making active antibodies from biological fluids

Fusion proteins comprising a portion of the HIV-1 Env protein (gp120 and gp140) and single-chain fragment V regions (ScFv) of an enhancing antibody that exhibits binding specificity for HIV-1 Env protein are disclosed that may serve in immunogenic formulations for vaccination against HIV-1 infection, as well as methods of generating an immune response using the fusion proteins.

Recombinant fusion protein comprising HIV gp120 linked to an enhancing CD4 binding site mAb

The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occn-panty of co-receptor present on the cell, for example. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CCR5 and CXCR4 sequences.

Virus coat protein/receptor chimeras and methods of use

The present invention relates to a composition and method for enhancing the efficacy of a vaccine in a subject treated with the vaccine by administering to the subject an antigen in conjunction with a chemokine.

Immuno-modulating effects of chemokines in DNA vaccination

The present invention relates to therapeutic compositions of macrophage derived chemokine (MDC) and methods for treating and preventing infection by a lentivirus, particularly an immunodeficiency virus, particularly HIV, using MDC proteins, nucleic acids and/or derivatives or analogues thereof. The present invention further relates to methods for detection and prognosis of lenivirus infection, particularly HIV infection using MDC as a prognostic indicator. The present invention further provides MDC proteins, nucleic acids encoding such proteins, that have amino-terminal sequences that differ from other MDC isolates. Recombinant host cells and methods of production are also provided.

Macrophage derived chemokine (MDC) as an anti-viral agent for the treatment and prevention of lentivirus infection

The present invention is directed to the discovery of antibodies that will react to proteins or nucleic acids bound to particular crosslinkers, but not to the free crosslinkers or free proteins or nucleic acids. Monoclonal antibodies with such binding specificity have widespread applications in receptor-ligand binding, immunodiagnostic and nucleic acid diagnostics.

Growing community of inventors

Alexandria, VA, United States of America

Anthony DeVico